Lexicon Pharmaceuticals Inc
NASDAQ:LXRX
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Lexicon Pharmaceuticals Inc
NASDAQ:LXRX
|
US |
|
Anicom Holdings Inc
TSE:8715
|
JP |
|
L
|
Leifheit AG
XMUN:LEI
|
DE |
|
Republic Bancorp Inc
NASDAQ:RBCAA
|
US |
|
Ibio Inc
F:0JV0
|
US |
|
Blackline Inc
NASDAQ:BL
|
US |
|
O
|
Orora Ltd
OTC:ORRAF
|
AU |
|
Elicera Therapeutics AB
F:8E8
|
SE |
|
U
|
United Bank Ltd
KAR:UBL
|
PK |
|
S
|
STL Technology Co Ltd
TPEX:4931
|
TW |
|
C
|
Cuscal Ltd
ASX:CCL
|
AU |
Shareholder Yield
Current shareholder yield for
LXRX is
hidden
.
Peers Comparison
Shareholder Yield
Buybacks
Buyback Yield measures how much a company reduces its outstanding shares through repurchases, expressed as a percentage.
This metric directly reflects the company’s efforts to return value to shareholders. By reducing the number of shares, buybacks can increase earnings per share and potentially boost the stock's price.
Peers Comparison
Buybacks
Debt Paydown
Debt Paydown Yield measures the amount of debt a company repays within a specific period, shown as a percentage of its market capitalization.
This metric indicates how the company is using its capital to decrease financial liabilities, which can strengthen its financial health and potentially enhance shareholder value.
Peers Comparison
Debt Paydown
Price Appreciation
LXRX Price
Lexicon Pharmaceuticals Inc
| Average Annual Return | -27.7% |
| Standard Deviation of Annual Returns | 28.4% |
| Max Drawdown | -95% |
| Market Capitalization | 1.1B USD |
| Shares Outstanding | 444 200 000 |
| Percentage of Shares Shorted | 10.8% |
LXRX Return Decomposition
Main factors of price return
Stock Splits
LXRX's latest stock split occurred on May 21, 2015
The company executed a 1-for-7 stock split, meaning that for every 7 shares held, investors received 1 new share.
Before the split, LXRX traded at 1.01 per share. Afterward, the share price was about 7.14.
The adjusted shares began trading on May 21, 2015. This was the only stock split in LXRX's history.